01—Abstract
Summary
Summary of the 8-K filed March 10, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) filed an 8-K on March 10, 2025 to disclose the appointment of Renée Galá to its Board of Directors.
The Board increased its size from ten to eleven directors and appointed Ms. Galá effective March 6, 2025, with her term expiring at the 2025 annual meeting of stockholders. The Board determined she is independent under Nasdaq listing standards and the Securities Act, and she has no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. The filing is governance-oriented rather than financially material.
Ms. Galá brings substantial life sciences finance and operations experience, including serving as President and Chief Operating Officer of Jazz Pharmaceuticals (greater than $4 billiona in 2024 revenues), previously as Jazz's CFO, and earlier as CFO of GRAIL and Theravance Biopharma. Her background in global commercial operations, R&D, business development, and international expansion may be relevant to DexCom as it pursues global growth in glucose biosensing. Compensation for Ms. Galá follows the standard non-employee director program: an initial RSU grant with a fair value of $500,000 vesting annually over three years, plus a pro-rated annual RSU grant of $56,986 tied to the 2025 Annual Meeting.
The filing also notes full acceleration of director equity awards upon a change in control. No financial results, guidance, or operational updates were disclosed.
02—Key points
Key Highlights
- Board expanded from ten to eleven directors with the appointment of Renée Galá, effective March 6, 2025.
- Ms. Galá was determined to be independent under Nasdaq listing standards and the Securities Act of 1933.
- Ms. Galá has no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
- Initial director equity grant of RSUs valued at $500,000, vesting annually over three years.
- Pro-rated annual director RSU grant valued at $56,986, based on days served before the 2025 Annual Meeting (base award $325,000).
- Ms. Galá brings experience as President and COO of Jazz Pharmaceuticals and prior CFO roles at Jazz, GRAIL, and Theravance Biopharma.
- Filing is governance-related; no financial results, guidance, or operational metrics were disclosed.
03—Questions
Frequently Asked Questions
Why is DexCom adding a director, and what expertise does she bring?
The company cited Ms. Galá's financial, strategic, and operational leadership across life sciences. Her background includes overseeing global commercial operations, R&D, manufacturing, and corporate strategy at Jazz Pharmaceuticals, as well as prior CFO experience and business development work, which align with DexCom's international expansion and growth priorities.
Does this appointment affect DexCom's financial results or guidance?
No. The 8-K contains no financial results, guidance, or operational updates. The financial impact is limited to the director compensation grants, which are modest relative to the company's size.
Is Ms. Galá considered independent?
Yes. The Board determined that she qualifies as an independent director under the Securities Act of 1933 and Nasdaq listing standards, and she has no undisclosed material interest in transactions with DexCom.
What compensation will Ms. Galá receive?
She received an initial RSU grant with a fair value of $500,000, vesting annually over three years, and will be eligible for a pro-rated annual RSU grant of $56,986 around the 2025 Annual Meeting. Director equity awards vest fully upon a change in control.
How long is Ms. Galá's initial term?
She will hold office until the 2025 annual meeting of stockholders, after which she would typically stand for election by shareholders.
04—Continue